Product Information
AMPHETAMINE ER 9.4 MG ODT is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $16.2178 per EA under NDC 00480331765. Its NADAC has been published 33 times since Feb 18, 2026.
FDA first approved this application on Jun 22, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
9.4 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480331765
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMPHETAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA209253FDA Approved
6/22/2023
TE Code
AB
On Market Since
12/8/2025
Pharmacological Classes
Price Statistics
The NADAC for AMPHETAMINE ER 9.4 MG ODT has been published 33 times since Feb 18, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $16.2178 per EA |
|---|---|
| All-time high | $16.4627 (Apr 15, 2026) |
| All-time low | $16.2178 (Sep 23, 2026) |
| 52-week high | $16.4627 |
| 52-week low | $16.2178 |
| Median price | $16.3201 |
| Average price | $16.3101 |
| Largest weekly change | -0.6% (Apr 22, 2026) |
| Weeks tracked | 33 |
| Tracking since | Feb 18, 2026 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amphetamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMPHETAMINE ER 9.4 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for AMPHETAMINE ER 9.4 MG ODT, manufactured by Teva Pharmaceuticals USA Inc., is $16.2178 per EA (NDC 00480331765), effective Sep 30, 2026.
How has the price of AMPHETAMINE ER 9.4 MG ODT changed over time?
Over the history we have for it, the NADAC for AMPHETAMINE ER 9.4 MG ODT has held within roughly two percent of its current level. It has been tracked across 33 weekly CMS publications since Feb 18, 2026.
What are the highest and lowest recorded NADAC prices for AMPHETAMINE ER 9.4 MG ODT?
Since Feb 18, 2026, the NADAC for AMPHETAMINE ER 9.4 MG ODT has ranged from a low of $16.2178 (Sep 23, 2026) to a high of $16.4627 (Apr 15, 2026), with a median of $16.3201 per EA.
Are there cheaper alternatives to AMPHETAMINE ER 9.4 MG ODT?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as AMPHETAMINE ER 9.4 MG ODT in a comparable dosage form, but none are currently priced below it.
Who manufactures AMPHETAMINE ER 9.4 MG ODT?
AMPHETAMINE ER 9.4 MG ODT (NDC 00480331765) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.